Patient responses to ipilimumab, a novel immunopotentiator for metastatic melanoma: How different are these from conventional treatment responses?

American Journal of Clinical Oncology: Cancer Clinical Trials

Volumn 35, Issue 6, 2012, Pages 606-611

  Pennock, Gregory K ^a   Waterfield, William ^b   Wolchok, Jedd D ^c  

^a M D ANDERSON CANCER CENTER ORLANDO   (United States)

^b Franklin Square Hospital Center   (United States)

^c MEMORIAL SLOAN KETTERING CANCER CENTER   (United States)

Author keywords

CTLA 4; ipilimumab; melanoma; response patterns

Indexed keywords

DACARBAZINE; IPILIMUMAB; MELANOCYTE PROTEIN PMEL 17; MELANOMA VACCINE;

ADVANCED CANCER; CANCER IMMUNIZATION; CANCER IMMUNOTHERAPY; CANCER SURVIVAL; DRUG EFFICACY; DRUG RESPONSE; HUMAN; METASTATIC MELANOMA; OVERALL SURVIVAL; PHASE 2 CLINICAL TRIAL (TOPIC); RANDOMIZED CONTROLLED TRIAL (TOPIC); REVIEW; SURVIVAL RATE;

ADJUVANTS, IMMUNOLOGIC; ANTIBODIES, MONOCLONAL; CTLA-4 ANTIGEN; HUMANS; MELANOMA; SKIN NEOPLASMS;

EID: 84870255287     PISSN: 02773732     EISSN: 1537453X     Source Type: Journal    
DOI: 10.1097/COC.0b013e318209cda9     Document Type: Review

References (45)

1. Faries MB. Evaluation of immunotherapy in the treatment of melanoma. Surg Oncol Clin N Am. 2006;15:399-418.
2. Houghton AN, Gold JS, Blachere NE. Immunity against cancer: Lessons learned from melanoma. Curr Opin Immunol. 2001; 13:134-140. (Pubitemid 32176030)
3. Anichini A, Vegetti C, Mortarini R. The paradox of T-cellmediated antitumor immunity in spite of poor clinical outcome in human melanoma. Cancer Immunol Immunother. 2004;53: 855-864. (Pubitemid 39312653)
4. Kalialis LV, Drzewiecki KT, Mohammadi M, et al. Spontaneous regression of metastases from malignant melanoma: A case report. Melanoma Res. 2008;18:279-283.
5. Drake CG, Jaffee E, Pardoll DM. Mechanisms of immune evasion by tumors. Adv Immunol. 2006;90:51-81. (Pubitemid 43765799)
6. Kim R, Emi M, Tanabe K, et al. Tumor-driven evolution of immunosuppressive networks during malignant progression. Cancer Res. 2006;66:5527-5536. (Pubitemid 43927099)
7. Ostrand-Rosenberg S. Immune surveillance: A balance between protumor and antitumor immunity. Curr Opin Genet Dev. 2008; 18:11-18. (Pubitemid 351694442)
8. Dougan M, Dranoff G. Immune therapy for cancer. Annu Rev Immunol. 2009;27:83-117.
9. Rosenberg SA, Dudley ME. Adoptive cell therapy for the treatment of patients with metastatic melanoma. Curr Opin Immunol. 2009;21:233-240.
10. Dudley ME, Yang JC, Sherry R, et al. Adoptive cell therapy for patients with metastatic melanoma: Evaluation of intensive myeloablative chemoradiation preparative regimens. J Clin Oncol. 2008;26:5233-5239.
11. National Comprehensive Cancer Network: CLINICAL Practice Guidelines in Oncology. Melanoma, Version 1.2010. Available at: Http://www.nccn.org. [Accessed September 30, 2010]
12. Schadendorf D, Algarra SM, Bastholt L, et al. Immunotherapy of distant metastatic disease. Ann Oncol. 2009;20(suppl 6):vi41-vi50.
13. Hauschild A. Adjuvant interferon alfa for melanoma: New evidence-based treatment recommendations? Curr Oncol. 2009; 16:3-6.
14. Hauschild A, Gogas H, Tarhini A, et al. Practical guidelines for the management of interferon-a-2b side effects in patients receiving adjuvant treatment for melanoma. Cancer. 2008;112:982-994. (Pubitemid 351304581)
15. Kruit WH, van Ojik HH, Brichard VG, et al. Phase 1/2 study of subcutaneous and intradermal immunization with a recombinant MAGE-3 protein in patients with detectable metastatic melanoma. Int J Cancer. 2005;117:596-604. (Pubitemid 41504547)
16. Van Baren N, Bonnet MC, Dre'no B, et al. Tumoral and immunologic response after vaccination of melanoma patients with an ALVAC virus encoding MAGE antigens recognized by T cells. J Clin Oncol. 2005;23:9008-9021. (Pubitemid 46211485)
17. Hoos A, Parmiani G, Hege K, et al. A clinical development paradigm for cancer vaccines and related biologics. J Immunother. 2007;30:1-15. (Pubitemid 46052199)
18. Wolchok JD, Hoos A, O'Day S, et al. Guidelines for the evaluation of immune therapy activity in solid tumors: Immune-related response criteria. Clin Cancer Res. 2009;15:7412-7420.
19. Greenfield EA, Nguyen KA, Kuchroo VK. CD28/B7 costimulation: A review. Crit Rev Immunol. 1998;18:389-418. (Pubitemid 28447017)
20. Peggs KS, Quezada SA, Korman AJ, et al. Principles and use of anti-CTLA4 antibody in human cancer. Curr Opin Immunol. 2006;16:206-213. (Pubitemid 43327304)
21. Weber J, Thompson JA, Hamid O, et al. A randomized, double-blind, placebo-controlled, phase II study comparing the tolerability and efficacy of ipilimumab administered with or without prophylactic budesonide in patients with unresectable stage III or IV melanoma. Clin Cancer Res. 2009;15: 5591-5598.
22. Wolchok JD, Neyns B, Linette G, et al. Ipilimumab monotherapy in patients with pretreated advanced melanoma: A randomised, double-blind, multicentre, phase 2, dose-ranging study. Lancet Oncol. 2010;11:155-164.
23. O'Day SJ, Maio M, Chiarion-Sileni V, et al. Efficacy and safety of ipilimumab monotherapy in patients with previously treated, advanced melanoma: A multicenter, single-arm, phase II study. Ann Oncol. 2010;21:1712-1717.
24. Hersh EM, O'Day SJ, Powderly J, et al. A phase II multicenter study of ipilimumab with or without dacarbazine in chemotherapynai ̈ve patients with advanced melanoma. Invest New Drugs. 2010. [Epub ahead of print].
25. O'Day S, Weber J, Lebbe C, et al. Effect of ipilimumab treatment on 18-month survival: Update of patients (pts) with advanced melanoma treated with 10 mg/kg ipilimumab in three phase II clinical trials. J Clin Oncol. 2009;27(suppl):15s. [Abstract 9033].
26. Hodi FS, O'Day SJ, McDermott DF, et al. Improved survival with ipilimumab in patients with metastatic melanoma. N Engl J Med. 2010;363:711-723.
27. O'Day S, Hodi FS, McDermott DF, et al. A phase III, randomized, double-blind, multicenter study comparing monotherapy with ipilimumab or gp100 peptide vaccine and the combination in patients with previously treated, unresectable stage III or IV melanoma. J Clin Oncol. 2010;28(suppl):7s. [Abstract 4].
28. Hodi FS, O'Day S, McDermott DF, et al. Re-induction with ipilimumab, gp100 peptide vaccine, or a combination of both from a phase III, randomized, double-blind, multicenter study of previously treated patients with unresectable stage III or IV melanoma. J Clin Oncol. 2010;28(suppl):7s. [Abstract 8509].
29. Lawrence DP, Hamid O, McDermott DF, et al. Phase II trial of ipilimumab monotherapy in melanoma patients with brain metastases. J Clin Oncol. 2010;28(suppl):7s. [Abstract 8523].
30. Saenger YM, Wolchok JD. The heterogeneity of the kinetics of response to ipilimumab in metastatic melanoma: Patient cases. Cancer Immun. 2008;8:1-7.
31. Weber J. Ipilimumab: Controversies in its development, utility, and autoimmune adverse events. Cancer Immunol Immunother. 2009;58:823-830.
32. Ribas A, Chmielowski B, Glaspy JA. Do we need a different set of response assessment criteria for tumor immunotherapy? Clin Cancer Res. 2009;15:7116-7118.
33. Hodi FS, Butler M, Obie DA, et al. Immunologic and clinical effects of antibody blockade of cytotoxic T lymphocyteassociated antigen 4 in previously vaccinated cancer patients. Proc Natl Acad Sci U S A. 2008;105:3005-3010. (Pubitemid 351723658)
34. Fong L, Small EJ. Anti-cytotoxic T-lymphocyte antigen-4 antibody: The first in an emerging class of immunomodulatory antibodies for cancer treatment. J Clin Oncol. 2008;26: 5275-5283.
35. Weber JS, O'Day S, Urba W, et al. Phase I/II study of ipilimumab for patients with metastatic melanoma. J Clin Oncol. 2008;26: 5950-5956.
36. Attia P, Phan GQ, Maker AV, et al. Autoimmunity correlates with tumor regression in patients with metastatic melanoma treated with anti-cytotoxic T-lymphocyte antigen-4. J Clin Oncol. 2005; 23:6043-6053.
37. Phan GQ, Yang JC, Sherry RM, et al. Cancer regression and autoimmunity induced by cytotoxic T lymphocyte-associated antigen 4 blockade in patients with metastatic melanoma. Proc Natl Acad Sci U S A. 2003;100:8372-8377. (Pubitemid 36842552)
38. Blansfield JA, Beck KE, Tran K, et al. Cytotoxic T-lymphocyteassociated antigen-4 blockage can induce autoimmune hypophysitis in patients with metastatic melanoma and renal cancer. J Immunother. 2005;28:593-598. (Pubitemid 41533093)
39. Beck KE, Blansfield JA, Tran KQ, et al. Enterocolitis in patients with cancer after antibody blockade of cytotoxic T-lymphocyteassociated antigen 4. J Clin Oncol. 2006;24:2283-2289. (Pubitemid 46630658)
40. Downey SG, Klapper JA, Smith FO, et al. Prognostic factors related to clinical response in patients with metastatic melanoma treated by CTL-associated antigen blockade. Clin Cancer Res. 2007;13:6681-6688. (Pubitemid 350206804)
41. Yang JC, Hughes M, Kammula U, et al. Ipilimumab (anti-CTLA4 antibody) causes regression of metastatic renal cell cancer associated with enteritis and hypophysitis. J Immunother. 2007;30: 825-830. (Pubitemid 350295361)
42. Maker AV, Yang JC, Sherry RM, et al. Intrapatient dose escalation of anti-CTLA-4 antibody in patients with metastatic melanoma. J Immunother. 2006;29:455-463. (Pubitemid 44288958)
43. Lutzky J, Wolchok J, Hamid O, et al. Association between immune-related adverse events (irAEs) and disease control or overall survival in patients (pts) with advanced melanoma treated with 10 mg/kg ipilimumab in three phase II clinical trials. J Clin Oncol. 2009;27(suppl):15s. [Abstract 9034].
44. Berman D, Parker SM, Chasalow SD, et al. Potential immune biomarkers of gastrointestinal toxicities and efficacy in patients with advanced melanoma treated with ipilimumab with or without prophylactic budesonide. J Clin Oncol. 2008;26(suppl):15s. [Abstract 3022].
45. Ku GY, Yuan J, Page DB, et al. Single institution experience with ipilimumab in advanced melanoma patients in the compassionate use setting: Lymphocyte count after two doses correlates with survival. Cancer. 2010;116:1767-1775.